Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ecolla
- Development stage
- Unknown
- Lead developer
- JETEMA
- Administration
- Subcutaneous, Intradermal
01
Overview
Ecolla is a biodegradable medical device developed by JETEMA, a South Korean biopharmaceutical company. It is a collagen stimulator composed of poly-L-lactic acid (PLLA) microparticles. When injected into the dermal or subcutaneous layers, Ecolla acts as a biostimulator, triggering the body's natural production of endogenous collagen. This process leads to gradual, natural-looking facial volumization and skin rejuvenation, with results typically lasting up to 24 months. It is primarily used in aesthetic dermatology for the correction of facial wrinkles and the restoration of lost volume associated with aging.
- Brand names
- Ecolla
- Other names
- Ecolla PLLA
Beyond the preview
Go deeper on Ecolla.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ecolla.